Pulmonary eosinophilia associated with montelukast

José Franco, María José Artés

Abstract

Antileukotriene drugs are new therapeutic agents that have recently been approved for the treatment of asthma. Several cases of eosinophilic conditions including Churg-Strauss syndrome have been reported to be associated with zafirlukast, a cysteinyl leukotriene type 1 receptor antagonist. So far no other leukotriene modifier has been associated with the syndrome. The case history is presented of a man with allergic rhinitis and asthma who had received intermittent pulse therapy with oral corticosteroids. Pulmonary eosinophilia developed while he was receiving treatment with montelukast, a chemically distinct cysteinyl leukotriene type 1 receptor antagonist. After discontinuation of montelukast therapy and administration of systemic corticosteroids the patient’s symptoms reversed rapidly and there was prompt resolution of the pulmonary infiltrates. We believe that cysteinyl leukotriene type 1 receptor antagonists are safe and effective drugs for most patients with asthma but caution is needed for those with more severe disease who require systemic corticosteroids, especially if they show characteristics of the atypical allergic diathesis seen in the prodromal phase of Churg-Strauss syndrome.

Case report

A 26 year old man with a three year history of asthma had received treatment with salbutamol, nedocromil, theophylline, and beclomethasone. There was a five year history of allergic rhinitis with positive skin tests for house dust mite and cat dander. Because asthma symptoms were not well controlled, treatment was started with fluticasone 1000 µg daily and salmeterol twice a day. Allergen immunotherapy was also prescribed. Nonetheless, short courses of oral prednisone 40 mg or deflazacort 60 mg daily were required on several occasions to control asthma exacerbations. A decision was made to initiate treatment with montelukast at a dose of 10 mg daily in the evening. Treatment with fluticasone was continued.

After approximately four months of treatment with montelukast the patient developed headache, malaise, myalgia, nasal congestion, and fever up to 39ºC. Oral cefuroxime and paracetamol were prescribed. Seven days later the patient developed dyspnoea and was admitted to our hospital.

On physical examination there were diffuse wheezes and ronchi. No cutaneous lesions or arthritis were found. A chest radiograph (fig 1) showed mixed alveolar-interstitial infiltrates in the upper lobes. Laboratory findings demonstrated a white blood cell count of 13.9 × 10³/l.

The antileukotriene drugs are new therapeutic agents which have recently been approved and are now available for the treatment of asthma in several countries. These drugs include one enzyme inhibitor of 5-lipoxygenase, zileuton, and three chemically distinct cysteinyl leukotriene type 1 receptor antagonists, zafirlukast, pranlukast and montelukast. Although clinical studies have shown that antileukotriene drugs are safe and effective, the results do not yet provide guidelines for their optimal clinical use in the treatment of asthma. As the use of these drugs increases, adverse events occurring at low frequency or in populations not examined in clinical trials may become manifest. Several cases of eosinophilic conditions including Churg-Strauss syndrome have been reported in patients who have been treated with zafirlukast. No other leukotriene modifier has yet been associated with the syndrome.

In this case report we describe an asthmatic patient in whom pulmonary eosinophilia developed while receiving montelukast therapy.

Figure 1  Posteroanterior radiograph of the chest showing mixed alveolar-interstitial infiltrates in both upper lobes.
Pulmonary eosinophilia associated with montelukast

Despite the lack of systemic vasculitis and a negative ANCA, this patient with his five year history of allergic rhinitis, progressive airways symptoms, and intermittent treatment with oral corticosteroids could have a forme frustre of Churg-Strauss syndrome.

Wechsler et al reported eight cases of Churg-Strauss syndrome following discontinuation of treatment with oral corticosteroids in patients with asthma receiving zafirlukast. The authors speculated that all these patients suffered from a primary eosinophilic infiltrative disorder that was unmasked when steroids were withdrawn. However, in two other cases of Churg-Strauss syndrome associated with zafirlukast therapy and in the case of pulmonary eosinophilia reported in this paper there was no association between corticosteroid withdrawal and the development of the syndrome. Because all these patients had moderate to severe asthma and had received intermittent or regular treatment with oral corticosteroids, they could have been forms frustres of Churg-Strauss syndrome whose manifestations were quelled by prior steroid treatment.

As this syndrome has not yet been seen in patients treated with zileuton, a drug that inhibits leukotriene B4 (LTB4) and cysteinyl leukotrienes (LTC4, LTD4 and LTE4), an alternative explanation based on the imbalance in leukotriene receptor stimulation has been put forward. Cysteinyl leukotriene type 1 receptor antagonism may have led to increased circulating LTB4 which has been shown to be a chemottractant for eosinophils as well as neutrophils.

Pulmonary eosinophilia associated with a cysteinyl leukotriene type 1 receptor antagonist other than zafirlukast suggests that the syndrome may be related to the effect of antileukotriene drugs on leukotriene receptors.

Churg-Strauss syndrome is a disorder characterised by hypereosinophilia and systemic vasculitis which occurs in a subset of patients with asthma and allergic rhinitis whose allergic diathesis is atypical with respect to the late age of onset of symptoms, frequent absence of family history, severity of upper respiratory tract disease, and exaggerated eosinophil response. The patient described here and the cases of Churg-Strauss syndrome associated with zafirlukast previously reported could belong to this category of patients. We hypothesise that, in such individuals, cysteinyl leukotriene type 1 receptor antagonists can precipitate the phase of the illness characterised by eosinophilic tissue infiltrates or life threatening systemic vasculitis.

We believe that cysteinyl leukotriene type 1 receptor antagonists remain safe and effective drugs for most patients with mild to moderate asthma but, while the exact causes of the syndrome are not well understood, caution is needed for those with more severe disease who require systemic corticosteroids, especially if they show characteristics of the atypical allergic diathesis seen in the prodromal phase of Churg-Strauss syndrome.

Discussion

Montelukast is a potent and selective cysteinyl leukotriene type 1 receptor antagonist with potency and oral activity similar to those of zafirlukast. At a dosage of 10 mg montelukast inhibits bronchospasm after allergen or exercise challenge and causes clinically significant improvement in patients with asthma. The tolerability profile of montelukast was similar to that of placebo in placebo controlled clinical trials in adults and children, and the most common adverse effect reported was headache.

In the case reported here the temporal relationship between montelukast treatment and the development of pulmonary eosinophilia suggests a causal association. However, we cannot exclude the possibility that the patient might have developed another eosinophilic condition such as allergic bronchopulmonary aspergillosis even without treatment with montelukast. The absence of parasites in the stools and the bronchoscopic specimens makes parasite induced eosinophilic lung disease unlikely.

with an eosinophil fraction of 0.14; the total IgE level was 527 IU/l and the results of an antineutrophil cytoplasmic antibody (ANCA) test were negative. A specimen of arterial blood, drawn while the patient was breathing room air, had a pH of 7.45 with oxygen tension (PaO2) of 8.7 kPa and carbon dioxide tension (PaCO2) of 5.0 kPa. A fibroptic bronchoscopic examination found no endobronchial lesions. Bronchoalveolar lavage fluid (fig 2) contained macrophages (10%), lymphocytes (10%), and eosinophils (80%). No acid-fast bacilli, fungi, or parasites were seen in the lavage fluid. Microscopic examination of a stool specimen disclosed no parasites.

Montelukast treatment was discontinued and treatment with intravenous methylprednisolone at a dosage of 60 mg daily was begun. Both dyspnoea and constitutional symptoms improved within a short time. After nine days of treatment with high dose systemic corticosteroids a chest radiograph revealed resolution of pulmonary infiltrates.

Figure 2 Bronchoalveolar lavage fluid showing a large number of eosinophils as well as scant macrophages. Papanicolaou stain; ×40.
Epithelioid haemangiendothelioma

M J Ledson, R Convery, A Carty, C C Evans

Abstract

Epithelioid haemangiendothelioma is a rare pulmonary neoplasm with less than 40 cases described world wide. We describe the only case to have presented with hypertrophic pulmonary osteoarthropathy who has been treated with azathioprine and has remained alive and well with no deterioration in pulmonary function since being diagnosed 16 years ago. The progression of the chest radiograph and spiral CT appearances of this rare neoplasm are described, and current views regarding the cellular origin of the neoplasm, its cytological appearance, clinical presentation and prognosis are discussed.

(Thorax 1999;54:560–561)

Keywords: epithelioid haemangiendothelioma; intravascular sclerosing bronchioalveolar tumour

Epithelioid haemangiendothelioma (EHE) (formerly known as intravascular sclerosing bronchioalveolar tumour, IVBAT) is a rare pulmonary neoplasm with less than 40 cases described world wide. We have described the first reported case presenting with hypertrophic pulmonary osteoarthropathy. We now report the progress of this patient who is unique in that she has been treated with azathioprine and has remained alive and well with no deterioration in pulmonary function since being diagnosed 16 years ago.

Case report

In April 1981 a 24 year old woman presented since being diagnosed 16 years ago. As the majority of her symptoms were due to the hypertrophic pulmonary osteoarthropathy indomethacin was commenced with good effect. Azathioprine was also started and the patient returned to work. The patient has been reviewed yearly for the past 16 years and her symptoms have remained unchanged. Increasing calcification of the nodules was seen radiologically by 1989, and by 1996 (fig 1) the overall number of nodules remained unchanged but their size had decreased to a maximum of 12 mm. A thoracic spiral intravenously enhanced CT scan was performed in 1997 (fig 2) showing innumerable 12 mm calcified nodules in all areas but more concentrated at the lung base posteriorly. Her chest radiograph, which had been normal six years earlier, showed multiple irregular, unequal, bilateral, uniformly distributed nodular shadowing. Full blood count, urea and electrolytes, liver function tests, calcium, and serum immunoglobulins were all normal. Autoantibodies including rheumatoid factor and anti-nuclear factor were negative, as was a Mantoux test. The erythrocyte sedimentation rate was 46 mm in the first hour. Pulmonary function tests revealed a mild restrictive ventilatory defect with lung volumes 70% predicted. Gas transfer was normal. No endobronchial lesions were found at fibreoptic bronchoscopy and a transbronchial lung biopsy specimen was unhelpful. The patient therefore underwent an open lung biopsy via a left thoracotomy. At operation multiple nodules up to 15 mm in diameter were found throughout the lung. Two wedge biopsies were taken from the lingula. All nodules had similar histological appearances which were considered typical of EHE.

Figure 1 Chest radiograph in 1996 revealing multiple irregular unequal bilateral calcified uniformly distributed nodular shadowing.

Figure 2 Spiral CT scan (enhanced with contrast) showing innumerable calcified nodules and diffuse fibrosis in both lungs.

bases and subpleurally. This CT scan also revealed about 20 low attenuation, non-enhancing, asymmetrically calcified liver lesions. In October 1995 azathioprine was discontinued. Her pulmonary function tests have not deteriorated over the past 16 years.

Discussion

EHE is a rare pulmonary neoplasm with fewer than 40 cases reported in the literature. The tumour was initially described in 1975 by Dail and Liebow and was named intravascular sclerosing bronchioalveolar tumour (IVBAT) because of the proposed bronchioalveolar origin of the neoplasm. Corrin et al. postulated that the tumour arose from precursor cells capable of differentiation along endothelial cell lines. Weldon-Linne et al., using electron microscopy, determined endothelial characteristics of the cells and thought they were derived from multipotential mesenchymal reserve cells. Using applied immunochemistry, Bhagavan et al. described diffuse cytoplasmic staining of tumour cells with factor VIII related antigen which binds to a storage product of endothelial cells.

Microscopically the initial change is an interstitial alveolar infiltrate with lymphocytes, followed by protrusion of the alveolar wall in a polypoidal manner into the alveolar lumen. This protrusion is covered with hypertrophied alveolar epithelial cells and its core consists at first of a mixoid type of connective tissue which stains positively with PAS and Congo Red. As the stroma matures it is converted into hyaline fibrous tissue. Embedded in this hyaline fibrous tissue are large malignant-appearing cells with large round to oval granary nuclei, often prominent nucleoli, and abundant homogeneously eosinophilic cytoplasm. Eventually the whole alveolus is obliterated. The same tissue that obliterates the alveoli may spread into and along the small bronchi and bronchioles and also fills small branches of the pulmonary arteries and veins. Thus multiple non-encapsulated parenchymal nodules are seen exhibiting a zonal architecture. There have been reports of nodules with calcification, chondrification, or even ossification, but this occurs in less than 10% of cases.

Weiss et al. first used the term EHE. It is now well recognised that the IVBAT is an EHE occurring in the lung which may also occur in the soft tissues, bone, and liver.

Three quarters of patients with EHE of the lung are women. The age range at presentation is wide (12–61 years), and 40% of patients are below the age of 30. Half the patients are asymptomatic and are discovered on incidental chest radiography. Symptoms are uncommon and are usually mild and include shortness of breath, mild pleuritic chest pain, and non-productive cough, although haemoptysis has been reported. However, hypertrophic pulmonary osteoarthropathy has not been previously reported. The chest radiograph usually reveals multiple bilateral pulmonary nodules and pleural effusions are rarely seen. Distant metastases are seen in less than a quarter of cases, the sites involved including the liver, lymph nodes, bowel, retroperitoneal soft tissues, and skin. In most cases the disease has a slowly progressive course and patients die 2–24 years after diagnosis of restrictive lung disease. The shortest survival is eight weeks in a patient who succumbed to gross haemoptysis. The longest survivor was treated surgically undergoing 11 separate resections over 24 years, finally succumbing to pneumonia superimposed on a decreasing respiratory function. Other treatments tried have been chemotherapy and radiotherapy with limited success in symptomatic patients near death. Our patient refused the empirical use of oral corticosteroids in an attempt to control potential fibrosis. She was therefore commenced on azathioprine following diagnosis and so far has had no deterioration in pulmonary function. However, at the patient’s request azathioprine was discontinued in October 1995. The patient is now the second longest survivor with this condition. She continues to have mild symptoms from her hypertrophic pulmonary osteoarthropathy but is asymptomatic from the pulmonary point of view and is still able to work as a paediatric nurse.

Pulmonary eosinophilia associated with montelukast

José Franco and María José Artés

Thorax 1999 54: 558-560
doi: 10.1136/thx.54.6.558

Updated information and services can be found at:
http://thorax.bmj.com/content/54/6/558

These include:

References
This article cites 8 articles, 0 of which you can access for free at:
http://thorax.bmj.com/content/54/6/558#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

Asthma (1782)
Vascularitis (53)
Pulmonary eosinophilia (14)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/